The major benefit to Marshall is an increase in funding which is gained from a royalty stream ownership interest in Vandalia due to our technology license.

The company also has the objective of commercializing novel biotechnology instrumentation and the advancement of biotechnology manufacturing techniques.

Since then we have created many more machines and have raised $500,000 to commercialize this technology.

Over the past two years, we have developed an innovative system and process for the mass production of specific DNA sequences with the polymerase chain reaction (PCR).